Dr. Reddy's Labs

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Dr. Reddy's (RDY) and Global Response Aid FZCO terminate the Avigan study conducted in Kuwait, focused on moderate-to-severe COVID patients in a hospital setting.

Dr. Reddy's (RDY) Ends Kuwait Study on Avigan for COVID-19

KUWAIT CITY, Jan. 27, 2021 /PRNewswire/ -- Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") and Global Response Aid FZCO (GRA) today announced results from an Avigan study on...

Dr. Reddy's and GRA Announce Clinically Meaningful Data from Avigan Pivotal Studies

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy's”) and Global Response Aid FZCO (GRA) today announced the termination of Avigan Trial Study conducted in Kuwait focused on moderate to severe COVID patients in a hospital setting. The hospitalized patient study, conducted in Kuwait, on moderate to severe patients was one of the studies in the overall clinical pro

Dr. Reddy's and GRA announces Avigan Pivotal Studies Update

Dr. Reddy's (RDY) receives approval from the DCGI to conduct a phase III study on the Sputnik V vaccine for the treatment of COVID-19 in India.

Dr. Reddy's (RDY) to Begin Phase III Study on Sputnik Vaccine

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced today that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India. The phase 3 study of Sputnik V will be conducted on 1500 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India. Earlier, the Data and Safety Monitoring Board (DSMB) revi

Dr. Reddy's Receives Approval to Conduct Phase 3 Clinical Trial for Sputnik V Vaccine in India

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that the independent Data and Safety Monitoring Board (DSMB) has reviewed the safety data from the phase 2 clinical trial of the Sputnik V vaccine and recommended the phase 3 recruitment and continue the clinical trial without any modifications. The phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-control

Sputnik V meets the primary endpoint of safety in the Phase 2 Clinical Trial in India

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the launch of Febuxostat Tablets, a therapeutic equivalent generic version of Uloric (Febuxostat) Tablets approved by the U.S. Food and Drug Administration (USFDA). The Uloric brand and generic had U.S. sales of approximately $108 million MAT for the most recent twelve months

Dr. Reddy's Laboratories announces the launch of Febuxostat Tablets in the U.S. Market

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) will announce results for the third quarter ended December 31, 2020 on Friday, January 29th, 2021 after the Board Meeting. Summary of Events Event     Date and Time     Medium Release of financial results January 29th, after the Board Meeting Stock Exchange, Media, Company website, Business wire, Email Press meet presentation Will be available on the Company's website Compan

Dr. Reddy's to Release Q3 FY 21 Results on January 29th, 2021

Baidu

Impala Platinum Holdings Ltd

Here we discuss four emerging market stocks, BCAUY, BIDU, IMPUY and RDY, which have solid growth prospects for 2021.

4 Emerging Market Stocks to Tap 2021 Economic Rebound

HYDERABAD, India & MISSISSAUGA, Ontario & HALIFAX, Nova Scotia--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy's”), Appili Therapeutics (TSX: APLI, OTCQX: APLIF) and Global Response Aid FZCO (GRA) today announced that Dr. Reddy's Canada has filed an application on behalf of the consortium for REEQONUS™ (favipiravir) Tablets for the acute treatment of mild to moderate COVID-19 adult patients und

Dr. Reddy's Laboratories, Global Response Aid, and Appili Therapeutics Announce the Filing of an Application for REEQONUS™ (favipiravir) Tablets for the Treatment of COVID-19 under Health Canada's Interim Order

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY referred to as “Dr. Reddy's”) today announced the secondary listing of its American Depository Receipts (ADRs) on NSE IFSC Limited under the symbol 'DRREDDY' on December 9, 2020. NSE IFSC Limited is a recognized international stock exchange established in the International Financial Services Centre (“IFSC”), GIFT City Gujarat, India. IFSC is one of the permissible jurisdictio

Secondary Listing of Dr. Reddy's ADRs on NSE IFSC Limited (GIFT City, Gujarat, India)

Bausch Health Companies Inc

Teva Pharmaceutical

3 Generic Drug Stocks to Watch Amid COVID-Induced Uncertainty

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), and Russian Direct Investment Fund (RDIF) announced today that they have commenced adaptive phase 2/3 clinical trials for Sputnik V vaccine in India after receiving the necessary clearance from the Central Drugs Laboratory, Kasauli, India. This will be a multicenter and randomized controlled study, which will include safety and immunogenicity study. The clinical trials are being conducted by

Dr. Reddy's and RDIF commence clinical trials for Sputnik V vaccine in India

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), Multiple-Dose Vials a therapeutic equivalent generic version of Quelicin® (Succinylcholine Chloride) Injection, 20 mg/mL, approved by the U.S. Food and Drug Administration (USFDA). The Quelicin® brand and generic ma

Dr. Reddy's Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced a preclinical data presentation for E7777 (denileukin diftitox), its engineered IL-2-diphtheria toxin fusion protein, at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting, being held virtually. Dr. Anil Namboodiripad, Senior Vice President and Head of Dr. Reddy's P

Dr. Reddy's Laboratories Presents Preclinical Data at SITC 2020 Demonstrating Significant Improvement in Tumor Growth Inhibition and Overall Survival Through a Combination of E7777 (Denileukin Diftitox) and an Immune Checkpoint Inhibitor

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced that it has signed a collaboration, development and supply agreement with Dr. Reddy's Laboratories Ltd. (BSE:500124, NSE:DRREDDY, NYSE:RDY, “Dr. Reddy's”) and Global Response Aid (“GRA”). This agreement follows on and is harmonized with the previously announced global licensing transaction (

Appili Therapeutics Joins Dr. Reddy's, Global Response Aid, and FUJIFILM in Advancing Avigan® Tablets for the Potential Treatment of COVID-19

Dr. Reddy's (RDY) earnings decline year over year while sales increase in second-quarter fiscal 2021.

Dr. Reddy's (RDY) Q2 Earnings Decline Y/Y, Sales Increase

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced its partnership with Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT), Government of India, for advisory support on clinical trials of Sputnik V vaccine in India. The partnership will allow Dr. Reddy's to identify and use some of BIRAC's clinical trial centres for the vaccine, which are funded under the National Biopharma Mission (NBM),

Dr. Reddy's partners with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India

Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q2 2021 Results - Earnings Call Transcript

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that Parag Agarwal will be joining the Company as Chief Financial Officer (Designate) on November 2, 2020. The Board of Directors at their meeting held today, has approved his appointment as a Chief Financial Officer (KMP*) of the Company effective December 1, 2020. In a career spanning over 33 years, Parag has held several leadership positions, contributing significantly to t

Dr. Reddy's Laboratories Announces Appointment of New Chief Financial Officer

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter and the half year ended September 30, 2020. The information mentioned in this release is on the basis of consolidated financial statements under International Financial Reporting Standards (IFRS). Q2 Performance Summary H1 Performance Summary   Rs. 4,897 Cr Rs. 9,314 Cr Revenue Revenue [Up: 11% QoQ; 2% YoY] [Up: 8% YoY]   53

Dr. Reddy's Q2 & H1 FY21 Financial Results

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy's”) today announced the re-launch of over-the-counter (OTC) Famotidine Tablets USP, 10 mg and 20 mg, the store-brand equivalents of Original Strength and Maximum Strength Pepcid AC®, in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy's OTC Famotidine Tablets USP, 10 mg and

Dr. Reddy's announces the re-launch of over-the-counter Famotidine Tablets USP, 10 mg and 20 mg, store-brand equivalent of Pepcid AC® in the U.S. Market

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, today announced that they have received approval from the Drug Control General of India (DCGI) to conduct an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in India. This will be a multi-center and randomized controlled study, which will include safety and immunogenicity study. Earlier in September 2020,

Dr. Reddy's and RDIF receive approval to conduct clinical trial for Sputnik V vaccine in India

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the second quarter ended September 30, 2020 on Wednesday, October 28th, 2020 after the Board Meeting. Summary of Events Event Date and Time Medium Release of financial results October 28th, after the Board Meeting Stock Exchange, Media, Company website, Business wire, Email Press meet presentation Will be available on the Company’s website Company’s website www.drred

Dr. Reddy's to Release Q2 FY 21 Results on October 28th, 2020

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has joined the Science Based Targets initiative’s (SBTi) business ambition for 1.5°C, becoming the first Indian and the third Asian pharmaceutical company to have set its Science-Based Targets to further minimize environmental impact. The Company has committed to reducing its Scope 1 and 2 greenhouse gas (GHG) emissions by 55 percent by 2030 from a FY2017-18 base year, which are in line with

News for Dr. Reddy's Labs Stock (RDY)